Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
08/2010
08/31/2010US7785838 Variants of mammalian prolactin, prolactin receptor antagonists, and methods of use
08/31/2010US7785835 A protein complex which includes a growth factor, growth factor binding protein and vitronectin; for treating cancers, psoriasis, atherosclerosis and wounds prone to hypertrophic scarring
08/31/2010US7785834 Soluble TNF receptors and their use in treatment of disease
08/31/2010US7785833 Methods and means for producing proteins with predetermined post-translational modifications
08/31/2010US7785829 polynucleotide encoding a soluble polypeptide; for decreasing inhibition of axonal growth of a central nervous system neuron; neurological diseases, disorders and injuries such as spinal cord injury
08/31/2010US7785825 Purified enzyme mixture capable of effecting dehydration and cyclization of precursor peptide; medicines; food processing; bioagriculture; drugs and cytotoxicity
08/31/2010US7785817 Using caudal-1 gene (CDX-1) as diagnostic indicator of stomach or esophageal cancer; immunodiagnostics
08/31/2010US7785812 Chemotherapy potentiation; drug discovery and design
08/31/2010US7785804 Mammalian CX3C chemokine antibodies
08/31/2010US7785803 Antibody diagnostic kits and methods of use
08/31/2010US7785801 Identification of surface-associated antigens for tumor diagnosis and therapy
08/31/2010US7785791 Polypeptide variants with altered effector function
08/31/2010US7785789 diagnosis autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED) in humans comprising detecting homozygosity or heterozygosity of a C to T nonsense mutation and an A to G missense mutation of a DNA sequence; cleavage with Taq 1 or another enzyme which cleaves recognition site 5'-TCGA-3'
08/31/2010US7785632 angiogenesis inhibitors; tetraiodothyroacetic acid conjugated to glycolide-lactide copolymer; binds cell surface receptor for thyroid hormone on integrin alpha at cell membrane level and does not activate signal transduction
08/31/2010US7785618 Conjugates comprising a biodegradable polymer and uses therefor
08/31/2010US7785617 Usable both as a scaffold for the growth of new tissue and as a delivery system or implant for pharmaceuticals, vaccines, hormones enzymes, and nutrients; high strength bonding between cell-compatible crosslinkers, e.g., biotin and/or avidin, and polymer, e.g., polyglycolic acid; diffusion; shaping
08/31/2010US7785608 Immunogenic compositions for the prevention and treatment of meningococcal disease
08/31/2010US7785604 nine residue peptides (ApoptoM) from flavivirus M ectodomain able to modulate specifically the apoptotic activity of diverse flavivirus; use for the treatment and/or the prevention of flavivirus-linked infections and cancers
08/31/2010US7785601 administering a hematopoietic growth factor such as granulocyte-colony stimulating factor and granulocyte-macrophage colony stimulating factor to a mammal
08/31/2010US7785599 Albumin fusion proteins
08/31/2010US7785589 biological fragments comprising polypeptides, in a combination with phosphatides, used for for immunization or treatment of ischemic cardiovascular disorders, in humans
08/31/2010US7785587 Mixture of corticosteroid and transforming growth factor inhibitor
08/31/2010US7785584 Ointment wound spray
08/31/2010US7785580 comprising a polypeptide coupled to a non-protein polymer selected from polyethylene glycol or polypropylene glycol, used for the treatment of respiratory system disorders such as asthma; increased plasma half-life
08/31/2010US7785579 enhancing the tumoricidal activity of an isolated TNF protein comprising bonding to the TNF to polyethyleneglycol; increased circulating half-life of the TNF while not increasing its toxicity; antitumor or anticarcinogenic agents with reduced side effects
08/31/2010US7785577 Melanocyte Stimulating Hormone; new peptides and peptidic conjugates containing at least 6 amino acids and including the sequence DPhe-Arg have a substantial activating effect on melanogenesis in the melanocytes of the hair bulb
08/31/2010US7785567 treatment of hypercholesterolemia or cardiovascular disease associated with atherosclerosis by administration of Growth Hormone Releasing Peptides to patient; reducing blood plasma cholesterol levels; modulating expression of scavenger receptor CD36 and genes involved in cellular cholesterol efflux
08/31/2010US7785566 useful in the treatment of heart failure, cardiac arrhythmias and other diseases where fibrosis is prominent such as in COPD, liver fibrosis, and atherosclerosis comprising a targeting moiety that demonstrates a higher binding affinity to the AT1 receptor than the native octapeptide Ang II
08/31/2010CA2332817C Il-6 antagonist peptides
08/31/2010CA2217871C Altered polypeptides with increased half-life
08/31/2010CA2190371C Receptor for oncostatin m
08/26/2010WO2010096838A2 Proproteins and methods of use thereof
08/26/2010WO2010096813A1 Krüppel-like factors and fat regulation
08/26/2010WO2010096769A1 Aqueous transfer buffer
08/26/2010WO2010096754A1 Compositions and methods to prevent and/or treat cancer with pa -card
08/26/2010WO2010096681A2 Modifications of cupredoxin derived peptides and methods of use thereof
08/26/2010WO2010096603A2 Cancer-targeting peptides and uses thereof in cancer therapy
08/26/2010WO2010096446A1 Use of g-csf for the extension of the therapeutic time-window of thrombolytic stroke therapy
08/26/2010WO2010096422A1 Biomolecule polymer conjugates and methods for making the same
08/26/2010WO2010096394A2 Aldehyde-tagged protein-based drug carriers and methods of use
08/26/2010WO2010096385A2 Methods and compositions for the treatment of autoimmune disease
08/26/2010WO2010096188A2 Analogues of neuropeptide y having proline substitution at position 34
08/26/2010WO2010096186A1 Analogues of neuropeptide y having at least one synthetic amino acid substitution
08/26/2010WO2010096175A1 Cytotoxic conjugates having neuropeptide y receptor binding compound
08/26/2010WO2010096142A1 Oxyntomodulin analogs
08/26/2010WO2010096134A1 Extended length botulinum toxin formulation for human or mammalian use
08/26/2010WO2010096125A1 Methods and kits for treating disease by administering insulin-like growth factor binding protein-2
08/26/2010WO2010096052A1 Oxyntomodulin analogs
08/26/2010WO2010096042A1 Mimotopes of hiv env
08/26/2010WO2010095978A2 Method for preparing a proinsulin preparation for peroral use
08/26/2010WO2010095881A2 Target activated cell/tissue translocation peptide for impermeable compound strategy, and uses thereof
08/26/2010WO2010095753A1 Novel compound, phosphorylation inhibitor, insulin resistance improving agent, agent to prevent or to treat diabetes, and screening method
08/26/2010WO2010095455A1 Hypo-immunogenic streptavidin and use thereof
08/26/2010WO2010095428A1 Foxm1 peptides and vaccines containing the same
08/26/2010WO2010095422A1 Therapeutic agent for malignant tumor
08/26/2010WO2010094906A1 The stabilisation of proteins
08/26/2010WO2010094905A1 Modified non-cytotoxic proteases
08/26/2010WO2010094900A1 Means for purifying a coagulation protein, and methods for implementing same
08/26/2010WO2010094734A2 Methods for identifying and compounds useful for the diagnosis and treatment of diseases involving inflammation
08/26/2010WO2010094463A1 Means and methods for manufacturing highly pure neurotoxin
08/26/2010WO2010094452A2 Novel composition
08/26/2010WO2010094085A1 Inhibition of multiple cell activation pathways
08/26/2010WO2010073104A3 Improving cognitive function
08/26/2010WO2010056988A9 Methods of treating stroke using stem cell-like menstrual blood cells
08/26/2010WO2010056657A8 Low viscosity highly concentrated suspensions
08/26/2010WO2010053517A3 Combination therapy to combat helminth resistance
08/26/2010WO2010045229A3 Protecting and repairing cartilage and musculoskeletal soft tissues
08/26/2010WO2010002478A4 Glycopeptide and uses thereof
08/26/2010WO2009140469A3 Dosage regimen comprising ap02l/trail, anti-vegf / anti-cd20 and chemotherapy to treat nsclc or non-hodgkin's lymphoma, respectively
08/26/2010WO2009135614A3 Use of a virus regimen for the treatment of diseases
08/26/2010WO2009091550A8 Sulfone substituted 2,3-dihydroimidazo [1,2-c] quinazoline derivatives useful for treating hyper-proliferative disorders and diseases with angiogenesis
08/26/2010WO2007072186A3 Use of alpha-msh for treatment of fibroproliferative disorders
08/26/2010US20100218267 Methods for Producing Antibodies
08/26/2010US20100216976 Sodium-independent transporter carrying acidic amino acid and its gene
08/26/2010US20100216867 Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
08/26/2010US20100216824 Anti-cancer cyclopenta [G]quinazonline compounds
08/26/2010US20100216733 Use of inhibitors and antisense oligonucleotides of btk for treating proliferative mastocytosis
08/26/2010US20100216726 Substituted-Quinoxaline-Type Piperidine Compounds and the Uses Thereof
08/26/2010US20100216725 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
08/26/2010US20100216724 Use of fibronectin fragment (196-203 ) as a therapeutic agent
08/26/2010US20100216723 Neuroprotection using nap-like and sal-like peptide mimetics
08/26/2010US20100216722 Use of the peptide pro-gly-thr-cys-glu-ile-cys-ala-tyr-ala-ala-cys-thr-gly-cys as a therapeutic agent
08/26/2010US20100216721 Inhibition of HIV-1 Infection by Potent Metallocene Conjugated Peptide Through Conformational Entrapment of Envelope GP120
08/26/2010US20100216720 Antibodies to troponin i and methods of use thereof
08/26/2010US20100216719 Soluble Fiber Combinations for Weight Control and Improving Parameters of Cardiovascular Health
08/26/2010US20100216718 Cancer Classification and Methods of Use
08/26/2010US20100216717 Hypoallergenic Mutant Polypeptides Based on Fish Parvalbumin
08/26/2010US20100216716 Cell-Permeable Peptide Inhibitors Of The JNK Signal Transduction Pathway
08/26/2010US20100216715 FGF21 Derivatives With Albumin Binder A-B-C-D-E- And Their Use
08/26/2010US20100216714 Natriuretic compounds, conjugates, and uses thereof
08/26/2010US20100216713 Novel compositions and methods in cancer associated with altered expression of prlr
08/26/2010US20100216712 Nucleic acid codifying for a utrophin transcription specific regulating protein, protein codified thereby and uses thereof
08/26/2010US20100216711 Protease-Stable, Cell Wall-Lysing Enzymes
08/26/2010US20100216710 Methods for stimulating nervous system regeneration and repair by regulating arginase i and polyamine synthesis
08/26/2010US20100216709 Systemic insulin-like growth factor-1 therapy reduces diabetic peripheral neuropathy and improves renal function in diabetic nephropathy
08/26/2010US20100216708 Fibronectin Type III Domain Based Scaffold Compositions, Methods and Uses
08/26/2010US20100216706 Ghrelin Protects Substantia Nigra Dopamine Neurons
08/26/2010US20100216705 Human growth hormone formulations
08/26/2010US20100216704 Novel genes and proteins that home to developing microvessels
08/26/2010US20100216703 Inhibitors of PDE4 and Methods of Use
1 ... 590 591 592 593 594 595 596 597 598 599 600 601 602 603 604 605 606 607 608 609 610 ... 3163